Coala Pro Kit

Coala Life and Bayer are expanding collaboration for home-enrollment to monitor cardiac patients

UPPSALA June 29, 2020 – Coala Life and the pharmaceutical company Bayer AB are expanding their collaboration to scale up operations in an effort to streamline the Swedish patient flow at a time when the healthcare system is under pressure. Coala Connect, a digital home-enrollment program for a healthcare service that enables remote arrhythmia assessments without the need of any physical meetings is now launched.

The elderly population in combination with cardiovascular disease are particularly at risk of adverse outcomes of covid-19 and are therefore encouraged to stay at home and limit close contact with other people. Minimizing unnecessary physical meetings will reduce the risk of exposure as well as lower the burden on the healthcare system. Coala Connect, which is a collaborative project between Coala Life and Bayer AB, enables Swedish healthcare providers to easily assess and diagnose patients with suspected arrhythmias at home.

The patients conduct their own investigation and record ECG and heart sound using a Coala Heart Monitor. Coala Life handles the entire logistics operation and the technical support to ensure that limited healthcare resources are used. The healthcare provider monitors patients remotely and can review all data in real time via the web-based portal Coala Care.

Coala Connect has been evaluated at Luthagen’s Specialist Clinic in Uppsala, which acted on the current situation and on the recommendations of Swedish authorities.

– In general, I think it is very good to be able to assess patients with Coala in their home environment. The Coala Connect service gives us the opportunity to avoid physical visits for our at-risk patients unless necessary. In the same way, Coala Connect also has a value for patients who, for other reasons, find it difficult to get to the clinic, due to disability or long distances. Sending a Coala directly to the patients’ home has also proven to free up time for our nurses, says Dr. Said Masiha, Head of Operations at Luthagen’s Specialist Clinic and specialist in cardiology/clinical physiology and internal medicine consultant

Coala Life and Bayer AB have a previous collaboration within atrial fibrillation diagnostics. Coala Connect is a new service that contributes to a solution for patients who are unable to physically visit healthcare. Bayer is a leading pharmaceutical company within the cardiovascular field and works to disseminate knowledge of innovative solutions and products aimed to improve people’s health and well-being.

For more information, please contact:
Dan Pitulia, CEO Coala Life AB, +46 70 972 08 38, dan.pitulia@coalalife.com
Ingalill Hyltander, Commercial Operation Director Bayer AB, +46 70 609 61 56, ingalill.hyltander@bayer.com

 

About Coala Life:
Coala Life is a Swedish digital health venture focused on cardiac diagnostics and digital health. The company has developed a portfolio of patented CE- and FDA-cleared medical products and services for user-centered digital remote monitoring and screening of the heart based on advanced and smart algorithms. Coala’s solutions enable analysis, remote monitoring, more effective cardiac assessments and integrated care services, all in real time. In 2019, Coala Life was recognized as one of the 100 Global Leaders in Digital Health by the Journal of mHealth. Follow your Heart® www.coalalife.com

About Bayer:
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com